CoTherix files for 4 million share follow-on offering

By Ted A. Knutson

Washington, Sept. 20 - CoTherix, Inc. filed for a follow-on offering of 4 million common shares in an S-1 registration with the Securities and Exchange Commission.

Selling shareholders will sell up to an additional 500,000 shares.

There is an over-allotment option for up to 675,000 shares.

Bookrunners are CIBC World Markets and UBS Investment Bank with Piper Jaffray and Needham & Co. also in the syndicate.

CoTherix, a South San Francisco biotechnology company, said proceeds from the offering primarily will be used for the marketing and development of its drug Venvatis and for general corporate purposes.

CoTherix stock closed at $14.04 on Tuesday.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.